A Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in Lower Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Myelodysplastic Syndromes/ Myeloproliferative Neoplasms (MDS/MPN)
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Luspatercept (Primary)
- Indications Anaemia
- Focus Therapeutic Use
Most Recent Events
- 07 Feb 2025 Status changed from active, no longer recruiting to recruiting.
- 08 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 09 Dec 2024 Planned primary completion date changed from 1 May 2025 to 20 Jun 2025.